PREVALENCE OF RUBELLA IGG ANTIBODIES AMONG PRODUCTIVE-AGE WOMEN IN AL-MAHWEET GOVERNORATE, YEMEN
Keywords:
Al-Mahweet, Antibody, IgG, Prevalence, Rubella virus, Women, YemenAbstract
Background: Rubella is an infectious viral disease that caused by the Rubella virus. The incidence of rubella infection in women during pregnancy leads to complications for fetus development and cause congenital rubella syndrome or fetal death. This study aimed to determine the prevalence rate of rubella among reproductive-age women in Al-Mahweet, Yemen.
Methods: A cross sectional study was conducted among females attending healthcare centers and schools from July 2007 to June 2008. Blood samples were collected individually from 270 females aged 15-35 years and the rubella virus IgG antibody was quantitated by enzyme-linked immunosorbent assay (ELISA). The needed data were collected by using a pretested questionnaire and analyzed by statistical program.
Results: Overall, 197(73%) had IgG-positive antibody to rubella and 73(27%) had IgG-negative antibody to rubella. The highest rate of anti-rubella IgG was among females aged 15-25 years and the lowest was among the females aged 31-35 years. Similarly, the higher rate was among females living in urban area compared to females from rural area. The statistically significant difference was found between most educational levels and positive results of anti-rubella IgG. With regard to marital status, the most frequent of rubella antibody was 72.3%, 73.1%, and 75.0%, respectively, recorded among single, married, and divorced females. The non-pregnant women had (73.7%) more incidence to rubella IgG antibody than pregnant (66.7%). 82.2% of IgG- positive women had no history of stillbirth and 65% had a history of stillbirth.
Conclusions: Most of the enrolled females had immunity against rubella virus, but still a significant percentage were susceptible to rubella infection. Thus, it is essential to introduce of rubella vaccine to control and prevent the rubella virus circulating among the community.
Peer Review History:
Received 1 June 2020; Revised 9 July; Accepted 20 August; Available online 15 September 2020
Academic Editor: Dr. DANIYAN Oluwatoyin Michael, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.com
Received file: Reviewer's Comments:
Average Peer review marks at initial stage: 6.0/10
Average Peer review marks at publication stage: 8.0/10
Reviewer(s) detail:
Dr. A.A. Mgbahurike, University of Port Harcourt, Nigeria, amaka_mgbahurike@yahoo.com
Dr. Tamer Elhabibi, Egyptian Russian University, Egypt, Tamer_elhabibi@yahoo.com
Rawaa S. Al-Kayali, Aleppo university, biochemistry and microbiology department, Syria, Rawah67@hotmail.com
Rola jadallah, Arab American University, Palestine, rolla.jadallah@aaup.edu
Downloads
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.